Sino Biopharmaceutical's (HKG:1177) zongertinib has been granted breakthrough therapeutic designation by China's National Medical Products Administration for the first-line treatment of non-small cell lung cancer, a late Wednesday Hong Kong bourse filing said.
Shares of the biopharmaceutical firm company were up over 3% in Thursday afternoon trading.
The grant was supported by the results of the Beamion LUNG-1 clinical trial of the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.